Treating Secondary-progressive MS (SPMS) - National Multiple Sclerosis Society

Skip to navigation Skip to content

Treating SPMS

Share

Modifying the Disease Course

The interferon beta medications (Avonex®, Betaseron®, Extavia® and Rebif®), Aubagio® (teriflunomide), Gilenya® (fingolimod), Tecfidere® (dimethyl fumarate), and Tysabri® (natalizumab) are approved by the FDA for use in relapsing forms of MS, which include those individuals who have transitioned to secondary-progressive MS but continue to have relapses. Therefore, a person who has been on one of the interferon medications during the initial relapsing-remitting phase of the disease will likely continue on it unless his or her physician feels that it is no longer doing an adequate job of controlling disease activity. At that time, the physician will likely recommend changing to Novantrone® (mitoxantrone), a chemotherapeutic agent: the only medication that has been approved by the FDA specifically for SPMS, as well as worsening relapsing MS.

Read more in The MS Disease-Modifying Medications (.pdf).

Managing symptoms

Regardless of the course of MS a person is experiencing, proactive symptom management is essential to maintaining comfort and productivity, and enhancing quality of life.

Rehabilitation

Rehabilitation specialists have an important role from the time of diagnosis helping people function optimally in spite of their MS, including enhancing mobility and promoting safety and independence.

Share